Showing results (241-250 of 259) with videos related to

Sort By:
Pageof 26
BMC Infectious Diseases|October 4, 2011
Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcomeAnnette C Reboli, Andrew F Shorr, Coleman Rotstein, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 29, 2015
Telavancin hospital-acquired pneumonia trials: impact of Gram-negative infections and inadequate Gram-negative coverage on clinical efficacy and all-cause mortalityMelinda K Lacy, Martin E Stryjewski, Whedy Wang, et al.
Transfusion|August 28, 2010
Comparison of platelet transfusion as fresh whole blood versus apheresis platelets for massively transfused combat trauma patients (CME)Jeremy G Perkins, Andrew P Cap, Philip C Spinella, et al.
Critical Care Medicine|March 4, 2026
Diagnostic Performance of Point-of-Care Immunoassay Measurements of Pancreatic Stone Protein for Sepsis Detection in ICU Patients: A Prospective, Multicenter, Biomarker-Blinded StudyAndrew F Shorr, Marin H Kollef, Richard G Wunderink, et al.
Open Forum Infectious Diseases|June 29, 2023
Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression AnalysisIgnacio Martin-Loeches, Andrew F Shorr, Marin H Kollef, et al.
Journal of Hospital Medicine|August 25, 2010
Hospitalizations with healthcare-associated complicated skin and skin structure infections: impact of inappropriate empiric therapy on outcomesMarya D Zilberberg, Andrew F Shorr, Scott T Micek, et al.
Critical Pathways in Cardiology|May 16, 2014
Emergency department patients with acute severe hypertension: a comparison of those admitted versus discharged in studying the treatment of acute hypertension registryKurt Kleinschmidt, Phillip Levy, Allison Wyman, et al.
Critical Care (London, England)|October 3, 2021
Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trialAndrew F Shorr, Christopher J Bruno, Zufei Zhang, et al.
The Lancet. Infectious Diseases|October 15, 2020
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trialRichard G Wunderink, Yuko Matsunaga, Mari Ariyasu, et al.
The Lancet. Infectious Diseases|May 14, 2023
Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)Keith S Kaye, Andrew F Shorr, Richard G Wunderink, et al.
Pageof 26